Literature DB >> 11704461

Comparative treatment planning between proton and X-ray therapy in pancreatic cancer.

D C Hsiung-Stripp1, J McDonough, H M Masters, W P Levin, S M Hahn, H A Jones, J M Metz.   

Abstract

With the utilization of new biologic agents and experimental chemotherapy in the treatment of pancreatic cancer, the issue of local-regional control will become increasingly important. This study was undertaken to determine the feasibility of dose escalation using proton therapy, as compared to conventional 3-dimensional conformal radiation, by minimizing the dose to normal tissues. The photon treatment plans of 4 patients with unresectable pancreatic cancer treated on a biologic therapy trial were utilized. Each patient was treated using a 3- or 4-field photon plan with 45 Gy to the clinical target volume (CTV), followed by a boost of 14.4 Gy to the gross target volume (GTV). Using a Helax treatment planning system, proton plans were generated to encompass the same CTV and GTV to the same prescribed dose. Dose-volume histograms (DVHs) were generated for the GTV, CTV, spinal cord, liver, and right and left kidneys. Each DVH was compared between the photon and proton plans. Proton plans utilized either a 2- or 3-field technique. Available energies included 130 or 180 MeV. Range modulators and bolus were used as needed to conform to the target volume. With the CTV and GTV receiving the same dose from the proton and photon plans, all individual proton plans were superior to the photon plans in reduction of normal tissue dose. For the 4 patients, the average dose reduction to 50% of the organ at risk was 78% to spinal cord (p = 0.003), 73% to left kidney (p = 0.025), 43% to right kidney (p = 0.059), and 55% to liver (p = 0.061). These comparative treatment plans show proton therapy results in significant reductions of dose to normal tissue compared to conventional photons while treating the same target volumes. This allows for the design of dose-escalation protocols using protons in combination with new biologic therapies and chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704461     DOI: 10.1016/s0958-3947(01)00072-3

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  9 in total

1.  Use of irreversible electroporation in unresectable pancreatic cancer.

Authors:  Robert C G Martin
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

Review 2.  Proton Therapy in the Management of Pancreatic Cancer.

Authors:  Jana M Kobeissi; Charles B Simone; Haibo Lin; Lara Hilal; Carla Hajj
Journal:  Cancers (Basel)       Date:  2022-06-04       Impact factor: 6.575

Review 3.  Proton therapy for pancreatic cancer.

Authors:  Romaine C Nichols; Soon Huh; Zuofeng Li; Michael Rutenberg
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

4.  Proton therapy may allow for comprehensive elective nodal coverage for patients receiving neoadjuvant radiotherapy for localized pancreatic head cancers.

Authors:  Richard Y Lee; Romaine C Nichols; Soon N Huh; Meng W Ho; Zuofeng Li; Robert Zaiden; Ziad T Awad; Bestoun Ahmed; Bradfors S Hoppe
Journal:  J Gastrointest Oncol       Date:  2013-12

5.  Particle radiation therapy for gastrointestinal malignancies.

Authors:  Jeffrey J Meyer; Brian G Czito; Christopher G Willett
Journal:  Gastrointest Cancer Res       Date:  2007

6.  Simulation study of dosimetric effect in proton beam therapy using concomitant boost technique for unresectable pancreatic cancers.

Authors:  Nobuyoshi Fukumitsu; Toshiyuki Okumura; Yuichi Hiroshima; Toshiki Ishida; Haruko Numajiri; Keiko Nemoto Murofushi; Kayoko Ohnishi; Teruhito Aihara; Hitoshi Ishikawa; Koji Tsuboi; Hideyuki Sakurai
Journal:  Jpn J Radiol       Date:  2018-05-10       Impact factor: 2.374

7.  Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer.

Authors:  Michael Chuong; Shahed N Badiyan; Man Yam; Zuofeng Li; Katja Langen; William Regine; Christopher Morris; James Snider; Minesh Mehta; Soon Huh; Michael Rutenberg; Romaine C Nichols
Journal:  J Gastrointest Oncol       Date:  2018-08

8.  Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer.

Authors:  Sarah Stefanowicz; Kristin Stützer; Sebastian Zschaeck; Annika Jakobi; Esther G C Troost
Journal:  Radiat Oncol       Date:  2018-11-22       Impact factor: 3.481

9.  Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: Gastrointestinal organs remain critical.

Authors:  Sarah Stefanowicz; Waldemar Wlodarczyk; Susanne Frosch; Sebastian Zschaeck; Esther G C Troost
Journal:  Clin Transl Radiat Oncol       Date:  2020-12-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.